Viral dynamics of primary HIV-1 infection in Senegal, West Africa

Journal of Infectious Diseases

Volumn 191, Issue 9, 2005, Pages 1460-1467

  Sarr, Abdoulaye Dieng ^a   Eisen, Geoffrey ^a   Guèye Ndiaye, Aïssatou ^b   Mullins, Christopher ^a   Traoré, Ibrahima ^b   Dia, Mamadou Ciré ^b   Sankalé, Jean Louis ^a   Faye, Diegane ^b   Mboup, Souleymane ^b   Kanki, Phyllis ^a  

^a Harvard AIDS Institute   (United States)

^b UNIVERSITÉ CHEIKH ANTA DIOP   (Senegal)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICA; ARTICLE; CORRELATION ANALYSIS; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MEASUREMENT; NONHUMAN; PRIORITY JOURNAL; SENEGAL; SEROCONVERSION; VIRUS LOAD; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; COHORT STUDIES; FEMALE; HIV ANTIBODIES; HIV-1; HUMANS; INCIDENCE; PHYLOGENY; PROSTITUTION; SENEGAL; VIRAL LOAD;

EID: 20244367931     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/429409     Document Type: Article

References (54)

1. Clark S, Shaw G. The acute retroviral syndrome and the pathogenesis of HIV-1 infection. Semin Immunol 1993; 5:149-55.
2. Daar ES, Moudgil T, Meyer RD, Ho DD. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med 1991; 324:961-4.
3. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med 1998; 339:33-9.
4. Lyles R, Munoz A, Yamashita T, et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. J Infect Dis 2000; 181:872-80.
5. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiological features of primary HIV infection. Ann Intern Med 1996; 125:257-64.
6. Clark S, Saag, M, Decker W, et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med 1991; 324:954-60.
7. Lyles C, Dorrucci M, Vlahov D, et al. Longitudinal human immunodeficiency virus type 1 load in the Italian Seroconversion Study: correlates and temporal trends of virus load. J Infect Dis 1999; 180:1018-24.
8. Busch MP, Lee LL, Satten GA, et al. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors. Transfusion 1995; 35:91-7.
9. Mellors J, Kingsley L, Rinaldo CJ, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122:573-9.
10. Fauci AS. Immunopathogenesis of HIV infection. J Acquir Immune Defic Syndr 1993; 6:655-62.
11. Mellors J, Rinaldo C Jr, Gupta P, White R, Todd J, Kingsley L. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167-70.
12. Lavreys L, Baeten J, Overbaugh J, et al. Virus load during primary human immunodeficiency virus (HIV) type 1 infection is related to the severity of acute HIV illness in Kenyan women. Clin Infect Dis 2002; 35:77-81.
13. Poss M, Martin H, Kreiss J, et al. Diversity in virus populations from genital secretions and peripheral blood from women recently infected with human immunodeficiency virus type 1. J Virol 1995; 69:8118-22.
14. Poss M, Overbaugh J. Variants from the diverse virus population identified at seroconversion of a clade A human immunodeficiency virus type 1-infected woman have distinct biological properties. J Virol 1999; 73:5255-64.
15. Richardson B, Mbori-Ngacha D, Lavreys L, et al. Comparison of human immunodeficiency virus type 1 viral loads in Kenyan women, men, and infants during primary and early infection. J Virol 2003; 77:7120-3.
16. Burke DS. Recombination in HIV: an important viral evolutionary strategy. Emerg infect Dis 1997; 3:253-9.
17. Gao F, Robertson DL, Morrison SG, et al. The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin. J Virol 1996; 70:7013-29.
18. Kaleebu P, French N, Mahe C, et al. Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infect Dis 2002; 185:1244-50.
19. Kanki PJ, Hamel DJ, Sankale JL, et al. Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis 1999; 179:68-73.
20. Neilson J, John G, Carr J, et al. Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya. J Virol 1999; 73:4393-403.
21. Renjifo B, Fawzi W, Mwakagile D, et al. Differences in perinatal transmission among human immunodeficiency virus type 1 genotypes. J Hum Virol 2001; 4:16-25.
22. Montavon C, Toure-Kane C, Liegeois F, et al. Most env and gag subtype A HIV-1 viruses circulating in West and West Central Africa are similar to the prototype AG recombinant virus IBNG. J Acquir Immune Defic Syndr 2000; 23:363-74.
23. Sankalé JL, Hamel D, Traore I, et al. Molecular evolution of HIV-1 subtype A in Senegal: 1988-1997. J Hum Virol 2000; 3:157-63.
24. Vanharmelen J, Wood R, Lambrick M, Rybicki EP, Williamson AL, Williamson C. An association between HIV-1 subtypes and mode of transmission in Capetown, South Africa. AIDS 1997; 11:81-7.
25. Kanki P, Travers K, Hernandez-Avila M, et al. Slower heterosexual spread of HIV-2 compared with HIV-1. Lancet 1994; 343:943-6.
26. Marlink R, Kanki P, Thior I, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994; 265:1587-90.
27. Travers K, Mboup S, Marlink R, et al. Natural protection against HIV-1 infection provided by HIV-2. Science 1995; 268:1612-5.
28. Abbott RC, Ndour-Sarr A, Diouf A, et al. Risk factors for HIV-1 and HIV-2 infection in pregnant women in Dakar, Senegal. J Acquir Immune Defic Syndr 1994; 7:711-7.
29. Gueye-Ndiaye A, Clark R, Samuel K, et al. Cost-effective diagnosis of HIV-1 and HIV-2 by recombinant-expressed env peptide (566/966) dot blot analysis. AIDS 1993; 7:475-81.
30. + lymphocyte counts. AIDS 1998; 12:131-7.
31. Popper S, Sarr AD, Gueye-Ndiaye A, Mboup S, Essex ME, Kanki P. Low plasma human immunodeficiency virus type 2 viral load is independent of proviral load: low virus production in vivo. J Virol 2000; 74:1554-7.
32. Popper S, Sarr AD, Travers KU, et al. Lower human immunodeficiency virus type 2 viral load reflects the difference in pathogenesis of HIV-1 and HIV-2. J Infect Dis 1999; 180:1116-21.
33. Mani I, Cao H, Hom D, et al. Plasma RNA viral load as measured by the branched DNA and nucleic acid sequence-based amplification assays of HIV-1 subtypes A and D in Uganda. J Acquir Immune Defic Syndr 1999; 22:208-9.
34. Murphy D, Cote L, Fauvel M, Rene P, Vincelette J. Multicenter evaluation of Roche COBAS Amplicor monitor version 1.5, Organon Tecknika NucliSens QT with extractor and Bayer quantiplex version 3.0 for the quantification of HIV-1 RNA in plasma. J Clin Microbiol 2000; 38:4034-41.
35. Parekh B, Phillips S, Granade T, Baggs J, Hu D, Respess R. Impact of HIV-1 subtypes variation on viral RNA quantification. AIDS Res Hum Retrovir 1999; 15:133-42.
36. Shuurman R, Descamps D, Weverling G, et al. Multicenter comparison of three commercial methods for quantification of HIV-1 RNA in plasma. J Clin Microbiol 1996; 34:3016-22.
37. Thompson JD, Gibson TJ, Plewnisk F, Jeanmougin F, Higgins DG. CLUSTAL X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 1997; 25:4876-82.
38. Long E, Martin H Jr, Kreiss J, et al. Gender differences in HIV-1 diversity at time of infection. Nat Med 2000; 6:71-5.
39. Meloni ST, Kim B, Sankale J, et al. Distinct human immunodeficiency virus type 1 subtype A virus circulating in West Africa: sub-subtype A3. J Virol 2004; 78:12438-45.
40. Laurent C, Diakhate N, Gueye N, et al. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS 2002; 16:1363-70.
41. Yerly S, Vora S, Rizzardi P, et al. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS 2001; 15:2287-92.
42. Michael N, Brown A, Voigt R, et al. Rapid disease progression without seroconversion following primary human immunodeficiency virus type 1 infection: evidence for highly susceptible human hosts. J Infect Dis 1997; 175:1352-9.
43. Morgan D, Mahe C, Whitworth J. Absence of a recognizable seroconversion illness in Africans infected with HIV-1. AIDS 2001; 15:1575-86.
44. O'Brien R, Rosenberg S, Yellin F, Goedert J. Longitudinal HIV-1 RNA levels in a cohort of homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:155-61.
45. Sterling R, Lyles M, Vlahov D, Astemborski J, Margolick B, Quinn C. Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters. J Infect Dis 1999; 180:666-72.
46. Rinke de Wit T, Tsegaye A, Wolday D, et al. Primary HIV-1 subtype C infection in Ethiopia. J Acquir Immune Defic Syndr 2002; 30:463-70.
47. Tien C, Chiu T, Latif A, et al. Primary subtype C HIV-1 infection in Harare, Zimbabwe. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:147-53.
48. Kuroda MJ, Schmitz JE, Charini WA, et al. Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys. J Immunol 1999; 162:5127-33.
49. + T cell responses associated with control of viremia. Science 1997; 278:1447-50.
50. Clerici M, Butto S, Lukwiya M, et al. Immune activation in Africa is environmentally-driven and is associated with upregulation of CCR5. Italian-Ugandan AIDS Project. AIDS 2000; 14:2083-92.
51. Carr JK, Laukkanen T, Salminen MO, et al. Characterization of subtype A HIV-1 from Africa by full genome sequencing. AIDS 1999; 13:1819-26.
52. Sarr AD, Sankalé JL, Hamel DJ, et al. Interaction with human immunodeficiency virus (type 2) predicts HIV-1 genotype. Virology 2000; 268:402-10.
53. Rowland-Jones S, Dong T, Krausa P, et al. The role of cytotoxic T-cells in HIV infection. Dev Biol Stand 1998; 92:209-14.
54. Rowland-Jones SL, McMichael A. Immune responses in HIV-exposed seronegatives: have they repelled the virus? Curr Opin Immunol 1995; 7:448-55.